Macuject operates in the healthcare sector, focusing on providing advanced AI-driven solutions to optimize the treatment of wet Age-Related Macular Degeneration (AMD). This condition, characterized by fluid leakage into the macula, is a leading cause of blindness among individuals over 60 in developed countries. Despite the availability of highly effective treatments, many patients do not receive optimal care. Macuject aims to bridge this gap by offering tools that assist clinicians in delivering precise and timely treatments, thereby improving patient outcomes.

The company's primary clients are healthcare providers and clinicians specializing in ophthalmology. Macuject's solutions are designed to integrate seamlessly into existing clinical workflows, enhancing the decision-making process through data-driven insights and predictive analytics.

Macuject operates on a B2B (business-to-business) model, generating revenue through the sale of its AI-driven software solutions to medical institutions and clinics. The company may also offer subscription-based services, providing continuous updates and support to its clients.

Keywords: AI-driven, wet AMD treatment, ophthalmology, predictive analytics, healthcare technology, clinical decision support, retina, macula, vision care, B2B.